Graham Capital Management’s Haemonetics HAE Stock Holding History

Graham Capital Management’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$321K	Buy	+5,691	New	+$371K	0.01%	795
2025 Q4	–	Sell	-5,116	Closed	-$249K	–	1373
2025 Q3	$249K	Sell	5,116 -1,300	-20%	-$80.5K	﹤0.01%	949
2025 Q2	$479K	Buy	+6,416	New	+$425K	0.01%	843
2024 Q2	–	Sell	-6,986	Closed	-$596K	–	1164
2024 Q1	$596K	Sell	6,986 -5,673	-45%	-$445K	0.01%	576
2023 Q4	$1.08M	Buy	+12,659	New	+$1.09M	0.02%	374
2023 Q3	–	Sell	-5,662	Closed	-$482K	–	1128
2023 Q2	$482K	Sell	5,662 -9,036	-61%	-$764K	0.01%	565
2023 Q1	$1.22M	Sell	14,698 -9,474	-39%	-$767K	0.04%	439
2022 Q4	$1.9M	Buy	24,172 +10,214	+73%	+$821K	0.06%	296
2022 Q3	$1.03M	Buy	+13,958	New	+$1M	0.04%	471

Other funds holding HAE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

RRAM

River Road Asset Management Louisville, Kentucky $8.99B AUM 12.83% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Graham Capital Management's HAE Position: Q1 2026 in Review

Graham Capital Management opened a new position in Haemonetics (HAE) in Q1 2026: 5,691 shares worth $321K. The stake represents 0.01% of the portfolio and ranks #795 among its holdings. This is a return to the name: Graham Capital Management previously reported a position in HAE as recently as Q3 2025.

Graham Capital Management first reported a position in HAE in Q3 2022 and has held it in 9 quarters since. The position peaked at $1.9M in Q4 2022. 324 funds tracked by Wall St. Rank hold HAE as of Q1 2026.

Graham Capital Management held 5,691 shares of Haemonetics worth $321K as of Q1 2026.
Haemonetics was a new Graham Capital Management position in Q1 2026.
Haemonetics made up 0.01% of Graham Capital Management's portfolio in Q1 2026, its #795 holding.
Graham Capital Management first reported a position in Haemonetics in Q3 2022 and has held it in 9 quarters since.
Graham Capital Management's Haemonetics position peaked at $1.9M in Q4 2022.
324 funds tracked by Wall St. Rank held Haemonetics as of Q1 2026.

Based on Graham Capital Management's 13F filing for Q1 2026, filed 15 May 2026.